more on VKTX Viking Therapeutics priced concurrent offerings of 7,857,143 shares at $35 each and $225M in convertible notes, with settlement scheduled for September 25, 2026. · Larger offerings: Viking increased both the stock offering and the note offering from their previously announced $200M sizes. · Note terms: The senior unsecured notes pay 2.00% annual interest and mature October 15, 2032. · Conversion price: The initial price is approximately $50.75 per share, about 45% abo

more on VKTX Viking Therapeutics priced concurrent offerings of 7,857,143 shares at $35 each and $225M in convertible notes, with settlement scheduled for September 25, 2026. · Larger offerings: Viking increased both the stock offering and the note offering from their previously announced $200M sizes. · Note terms: The senior unsecured notes pay 2.00% annual interest and mature October 15, 2032. · Conversion price: The initial price is approximately $50.75 per share, about 45% above the stock offering price. · Estimated proceeds: Viking expects approximately $258.2M net from stock and $218.0M net from notes, excluding underwriter options. · Funding plans: Proceeds will support the VK2735 and VK3019 programs, other research and development, working capital, and general corporate purposes.